Morphic Holding, Inc. (MORF)
Company Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer.
Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; and preclinical trial to treat idiopathic pulmonary fibrosis and fibrosis diseases.
The company is also developing avß6 for the treatment of fibrotic diseases, and avß8 to treat solid tumors, as well as various other products. Morphic Holding, Inc. has a research collaboration with Engitix Ltd for the identification of Morphic integrin technology amenable targets in fibrostenotic IBD; a collaboration agreement with Schrödinger, LLC for integrin targets; and a license agreement with Children's Medical Center Corporation to develop and commercialize products worldwide for any therapeutic or diagnostic use in humans and veterinary applications.
It also has collaboration agreements with AbbVie Biotechnology Ltd and Janssen Pharmaceuticals, Inc. to discover or develop integrin-based therapeutics.
Morphic Holding, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2014 |
| IPO Date | Jun 27, 2019 |
| Industry | Biotechnology |
| Sector | Health Care |
| Employees | 100 |
Contact Details
Address:
35 Gatehouse Dr # A2 Waltham, Massachusetts 02451-1215 United States | |
| Phone | 781 996 0955 |
| Website | morphictx.com |
Stock Details
| Ticker Symbol | MORF |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | US Dollars |
| IPO Price | $15.00 |
| CIK Code | 1679363 |
| CUSIP Number | 61775R105 |
| ISIN Number | US61775R1059 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Praveen P. Tipirneni M.D. | Chief Executive Officer, MD and Director |
| Dr. Bruce N. Rogers Ph.D. | President |
| Dr. Timothy A. Springer Ph.D. | Founder, Independent Director and Member of Scientific Advisory Board |
| Dr. Marc Schegerin M.B.A., M.D. | Chief Financial Officer and Chief Operating Officer |
| William D. DeVaul Esq. | General Counsel and Secretary |
| Robert E. Farrell Jr., CPA, CPA | Senior Vice President of Finance and Operations and Chief Accounting Officer |
| Dr. Blaise Lippa Ph.D. | Chief Scientific Officer |
| Aaron Pelta | Senior Vice President of Business and Corporate Development |
| Joanne Gibbons | Senior Vice President of Regulatory Affairs |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 21, 2022 | 8-K | Current report |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 10, 2022 | 4 | Statement of changes in beneficial ownership of securities |
| Jun 9, 2022 | 8-K | Current report |